In this case report, we present a patient who developed dermatological adverse reactions following vortioxetine use.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Major depressive disorder is the second-largest healthcare problem worldwide in terms of illness-induced disability, and second-generation antidepressants are the most commonly used treatments in this disorder.
📊
Key Findings & Data:Vortioxetine is a recently introduced antidepressant with a multimodal mechanism of action.
💡
Conclusion & Impact:In this case report, we present a patient who developed dermatological adverse reactions following vortioxetine use.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Major depressive disorder is the second-largest healthcare problem worldwide in terms of illness-induced disability, and second-generation antidepressants are the most commonly used treatments in this disorder. Vortioxetine is a recently introduced antidepressant with a multimodal mechanism of action. Some side effects associated with the use of vortioxetine have been reported. Side effects that do not occur in clinical trials can be reported during phase IV studies. In this case report, we present a patient who developed dermatological adverse reactions following vortioxetine use.
🔖
Cite This Article
OKUMUS, B., KARATAS, K. S., KOC, A. E. (2020). A serious dermatological side effect due to vortioxetine: a case report. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 33 - Sayı: 1, 87–91. https://ajindex.com/articles/149869
Sagud M, Nikolac Perkovic M, Vuksan-Cusa B, Maravic A, Svob Strac D, Mihaljevic Peles A, et al. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology (Berl) 2016; 233:3259-3267
Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, et al. Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep 2017; 69:595-601
Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry 2015; 76:575-582
Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016; 30:242-252
Cetin M, Kose S. Serious dermatological adverse effects of vortioxetine: Two cases. Psychiatry and Clinical Psychopharmacology 2018; 28:355-357
Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol 2015; 19
Theunissen EL, Street D, Højer AM, Vermeeren A, van Oers A, Ramaekers JG. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013; 93:493-501
Subeesh V, Singh H, Maheswari E, Beulah E. Novel adverse events of vortioxetine: a disproportionality analysis in USFDA adverse event reporting system database. Asian J Psychiatr 2017; 30:152-156
Ay R, Aytas O. Acneiform eruption associated with the use of vortioxetine. Psychiatry and Clinical Psychopharmacology 2019; 29:226-228. (Turkish
Herstowska M, Komorowska O, Cubała WJ, Jakuszkowiak-Wojten K, Gałuszko-Węgielnik M, Landowski J. Severe skin complications in patients treated with antidepressants: a literature review. Postepy Dermatol Alergol 2014; 31:92-97
Shah B, Levenson JL. Use of psychotropic drugs in the dermatology patient: when to start and stop? Clin Dermatol 2018; 36:748-755
Ford HE, Jenike MA. Erythema multiforme associated with trazodone therapy. J Clin Psychiatry 1985; 46:294-295